The 5-year data strengthens the case for TransCon PTH as a long-term treatment for hypoparathyroidism, potentially expanding its addressable market and supporting pricing negotiations. Traders should watch for upcoming regulatory milestones (e.g., FDA decision or label expansion) and commercial launch updates. The high completion rate and sustained efficacy reduce clinical risk.
Price Chart
Executive Summary
Ascendis Pharma announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial for TransCon PTH in hypoparathyroidism, showing sustained efficacy and safety. Key results include 82% responder rate on the multi-component endpoint, normalized serum calcium in 88% of patients, independence from active vitamin D in 96%, and maintained kidney function improvements. The data reinforces the drug's long-term profile, which is positive for the ongoing regulatory and commercial narrative.
Key Facts
- 82% of patients met the multi-component endpoint (normal serum calcium, no active vitamin D, <600 mg/day calcium) at Week 266.
- 88% of patients had normal albumin-adjusted serum calcium (mean 9.0 mg/dL).
- 96% achieved independence from active vitamin D; 95% from therapeutic calcium doses.
- Mean eGFR increased by 9.4 mL/min/1.73 m² from baseline to Week 266, sustained over 5 years.
- 95% (56/59) of patients completed the 5-year trial; no discontinuations related to study drug.
- No new safety signals; one patient had transient, non-neutralizing anti-PTH antibodies without impact.
Financial Impact
No financial figures provided; the data supports the commercial potential of TransCon PTH in hypoparathyroidism, a condition with limited treatment options.
Risk Factors
- Regulatory delays or additional trial requirements for label expansion.
- Competition from other therapies (e.g., Eneboparatide, AZP-3601) in development.
- Commercial execution risk: adoption by endocrinologists and payer coverage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-268415 |
| Document: 0001193125-26-268415-index-headers.html | 0001193125-26-268415 |
| Document: 0001193125-26-268415-index.html | 0001193125-26-268415 |
| Document: 0001193125-26-268415.txt | 0001193125-26-268415 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access